Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 8:blood.2023022908.
doi: 10.1182/blood.2023022908. Online ahead of print.

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Rahul S Vedula  1 , Hannah Q Karp  1 , Jeremy Koob  2 , Felicia Lim  1 , Jacqueline S Garcia  1 , Eric S Winer  1 , Marlise R Luskin  1 , Gabriel Ghiaur  3 , Annette S Kim  4 , Lan W Beppu  5 , Olga Sala-Torra  5 , Jerald P Radich  6 , Jonathan Samuel Gootenberg  7 , Omar Abudayyeh  8 , Feng Zhang  9 , R Coleman Lindsley  1
Affiliations

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Rahul S Vedula et al. Blood. .

Abstract

Fusion oncogenes can be cancer-defining molecular alterations that are essential for diagnosis and therapy selection.1,2 Rapid and accessible molecular diagnostics for fusion-driven leukemias such as acute promyelocytic leukemia (APL), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and chronic myeloid leukemia (CML) are unavailable, creating a barrier to timely diagnosis and effective targeted therapy in many healthcare settings, including community hospitals and low-resource environments. We developed CRISPR-based RNA-fusion transcript detection assays using SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) for the diagnosis of fusion-driven leukemias. We validated these assays using diagnostic APL and CML patient samples from academic centers and dried blood spots from low-resource environments, demonstrating 100% sensitivity and specificity. We identified assay optimizations to enable the use of these tests outside of tertiary cancer centers and clinical laboratories, enhancing the potential impact of this technology. Rapid point-of-care diagnostics can improve outcomes in cancer patients by expanding access to therapies for highly treatable diseases that would otherwise lead to serious adverse outcomes due to delayed or missed diagnoses.

PubMed Disclaimer

Similar articles

See all similar articles

LinkOut - more resources